Septic Shock - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Septic Shock - Pipeline Review, H2 2016’, provides an overview of the Septic Shock pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Septic Shock, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Septic Shock and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Septic Shock

The report reviews pipeline therapeutics for Septic Shock by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Septic Shock therapeutics and enlists all their major and minor projects

The report assesses Septic Shock therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Septic Shock

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Septic Shock

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Septic Shock pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adrenomed AG

Ferring International Center S.A.

Huons Co., Ltd.

InflaRx GmbH

Inotrem S.A.

Lixte Biotechnology Holdings, Inc.

Noxxon Pharma AG

Octapharma AG

Orion Oyj

Peptinov ...

Adrenomed AG

Ferring International Center S.A.

Huons Co., Ltd.

InflaRx GmbH

Inotrem S.A.

Lixte Biotechnology Holdings, Inc.

Noxxon Pharma AG

Octapharma AG

Orion Oyj

Peptinov SAS

Pharmazz, Inc.

Spider Biotech

Takeda Pharmaceutical Company Limited

Therashock, LLC

ViiV Healthcare Limited

XImmune AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Septic Shock ...

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Septic Shock Overview 9

Therapeutics Development 10

Pipeline Products for Septic Shock - Overview 10

Pipeline Products for Septic Shock - Comparative Analysis 11

Septic Shock - Therapeutics under Development by Companies 12

Septic Shock - Therapeutics under Investigation by Universities/Institutes 14

Septic Shock - Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Septic Shock - Products under Development by Companies 19

Septic Shock - Products under Investigation by Universities/Institutes 20

Septic Shock - Companies Involved in Therapeutics Development 21

Adrenomed AG 21

Ferring International Center S.A. 22

Huons Co., Ltd. 23

InflaRx GmbH 24

Inotrem S.A. 25

Lixte Biotechnology Holdings, Inc. 26

Noxxon Pharma AG 27

Octapharma AG 28

Orion Oyj 29

Peptinov SAS 30

Pharmazz, Inc. 31

Spider Biotech 32

Takeda Pharmaceutical Company Limited 33

Therashock, LLC 34

ViiV Healthcare Limited 35

XImmune AB 36

Septic Shock - Therapeutics Assessment 37

Assessment by Monotherapy Products 37

Assessment by Target 38

Assessment by Mechanism of Action 40

Assessment by Route of Administration 42

Assessment by Molecule Type 44

Drug Profiles 46

3K3A-APC - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

adrecizumab - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

AM-12 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Aspidasept - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

BC-1215 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

BMS-936559 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

BTZO-2 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Drug for Sepsis and Septic Shock - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

HBN-1 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

HBN-3 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

HBN-4 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

HU-003 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

IFX-1 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

L-257 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

LB-100 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

levosimendan - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

M-6229 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Motrem - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

NOXD-21 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

PMZ-2010 - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

pooled plasma (human) - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Proteins to Inhibit Nuclear Factor Kappa B for Septic Shock - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

R-190 - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

SB-056 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

selepressin - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Small Molecule to Inhibit TNF-Alpha for Septic Shock - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

SP-14 - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

SP-9 - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Septic Shock - Dormant Projects 83

Septic Shock - Discontinued Products 85

Septic Shock - Product Development Milestones 86

Featured News & Press Releases 86

Sep 13, 2016: Inotrem Successfully Completes Its First Phase I Clinical Trial with Motrem, a TREM-1 Pathway Modulator for the Treatment of Septic Shock 86

Jun 07, 2016: InflaRx initiates phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients undergoing complex cardiac surgery 86

Jan 28, 2016: InflaRx announces positive phase IIa top-line results from the SCIENS trial investigating IFX-1, a first-in-class anti-complement C5a antibody 87

Oct 08, 2015: Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan 88

Jun 16, 2015: Tenax Therapeutics Highlights New Scientific Publication Regarding the Potential Mortality Benefits of Levosimendan in Septic Shock Patients 89

Jan 02, 2013: Adrenomed Develops New Drug To Reduce Mortality From Septic Shock 90

Appendix 91

Methodology 91

Coverage 91

Secondary Research 91

Primary Research 91

Expert Panel Validation 91

Contact Us 91

Disclaimer 92

List of Tables

List of Tables

Number of Products under Development for Septic Shock, H2 2016 10

Number of Products under Development for Septic Shock - Comparative Analysis, ...

List of Tables

Number of Products under Development for Septic Shock, H2 2016 10

Number of Products under Development for Septic Shock - Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Development, H2 2016 17

Comparative Analysis by Unknown Stage Development, H2 2016 18

Products under Development by Companies, H2 2016 19

Products under Investigation by Universities/Institutes, H2 2016 20

Septic Shock - Pipeline by Adrenomed AG, H2 2016 21

Septic Shock - Pipeline by Ferring International Center S.A., H2 2016 22

Septic Shock - Pipeline by Huons Co., Ltd., H2 2016 23

Septic Shock - Pipeline by InflaRx GmbH, H2 2016 24

Septic Shock - Pipeline by Inotrem S.A., H2 2016 25

Septic Shock - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016 26

Septic Shock - Pipeline by Noxxon Pharma AG, H2 2016 27

Septic Shock - Pipeline by Octapharma AG, H2 2016 28

Septic Shock - Pipeline by Orion Oyj, H2 2016 29

Septic Shock - Pipeline by Peptinov SAS, H2 2016 30

Septic Shock - Pipeline by Pharmazz, Inc., H2 2016 31

Septic Shock - Pipeline by Spider Biotech, H2 2016 32

Septic Shock - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 33

Septic Shock - Pipeline by Therashock, LLC, H2 2016 34

Septic Shock - Pipeline by ViiV Healthcare Limited, H2 2016 35

Septic Shock - Pipeline by XImmune AB, H2 2016 36

Assessment by Monotherapy Products, H2 2016 37

Number of Products by Stage and Target, H2 2016 39

Number of Products by Stage and Mechanism of Action, H2 2016 41

Number of Products by Stage and Route of Administration, H2 2016 43

Number of Products by Stage and Molecule Type, H2 2016 45

Septic Shock - Dormant Projects, H2 2016 83

Septic Shock - Dormant Projects (Contd..1), H2 2016 84

Septic Shock - Discontinued Products, H2 2016 85

List of Figures

List of Figures

Number of Products under Development for Septic Shock, H2 2016 10

Number of Products under Development for Septic Shock - Comparative Analysis, ...

List of Figures

Number of Products under Development for Septic Shock, H2 2016 10

Number of Products under Development for Septic Shock - Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy Products, H2 2016 37

Number of Products by Top 10 Targets, H2 2016 38

Number of Products by Stage and Top 10 Targets, H2 2016 38

Number of Products by Top 10 Mechanism of Actions, H2 2016 40

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 40

Number of Products by Routes of Administration, H2 2016 42

Number of Products by Stage and Routes of Administration, H2 2016 42

Number of Products by Molecule Types, H2 2016 44

Number of Products by Stage and Molecule Types, H2 2016 44

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports